Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD PhD, Koji Kato, MD PhD, Hideo Harigae, MD PhD, Marie José Kersten, MD PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz C. Offner, MD PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD, Catherine Thieblemont, MD PhD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138983

Published: 2020

Journal Articles

Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Åsa Lindberg, III, Christian Winther Eskelund, Alexandra Albertsson-Lindblad, MD PhD, Arne Kolstad, MD PhD, Anna Laurell, MD PhD, Riikka Räty, MD PhD, Kirsten Grønbæk, Prof,MDDMSc, Christian H. Geisler, MD PhD, Mats Jerkeman, MD PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-133370

Published: 2020

Journal Articles

Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma

Ivana Spasevska, Sarah Josefsson, PhD MSc, Yngvild Nuvin Blaker, MD PhD, Chloe B. Steen, PhD, Ankush Sharma, PhD, Kushi Kushekhar, PhD MSc, Saskia Meyer, PhD, Arne Kolstad, MD PhD, Klaus Beiske, MD PhD, Harald Holte, MD PhD, Bjørn Østenstad, MD PhD, Eva Kimby, MD PhD, Johanna Olweus, PhD, Kjetil Tasken, PhD, Suzanne Lorenz, PhD, Erlend B. Smeland, PhD MD, Ash A. Alizadeh, MD PhD, Kanutte Huse, PhD, June Helen Myklebust, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142380

Published: 2020

Journal Articles

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Mats Jerkeman, MD PhD, Martin Hutchings, MD PhD, Riikka Räty, MD PhD, Karin Fahl Wader, MD PhD, Anna Laurell, MD PhD, Jacob H. Christensen, MD, Hanne Kuitunen, MD, Christian Winther Eskelund, MD PhD, Kirsten Groenbaek, MD DMSc, Carsten Utoft Niemann, MD PhD, Christian H. Geisler, MD PhD, Arne Kolstad, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-133298

Published: 2020

Journal Articles

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

Mats Jerkeman, MD PhD, Arne Kolstad, MD PhD, Carsten Utoft Niemann, MD PhD, Kirsten Groenbaek, MD DMSc, Martin Hutchings, MD PhD, Annika Pasanen, MD PhD, Sara Ekberg, Karin Fahl Wader, MD PhD, Ingrid Glimelius, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-133273

Published: 2020

Journal Articles

A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies

Mette Dahl, MD, Simon Husby, MD, Christian Winther Eskelund, MD, Christophe Côme, PhD, Sara Ek, PhD Professor, Arne Kolstad, MD PhD, Riikka Räty, PhD Associate professor, Mats Jerkeman, MD Professor, Christian H. Geisler, MD PhD, Lasse Sommer Kristensen, PhD Assistant professor, Kirsten Grønbæk, Professor, MD DMSc

Blood (2019) 134 (Supplement_1): 1495.

https://doi.org/10.1182/blood-2019-123989

Published: 2019

Journal Articles

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Martin Dreyling, MD, Marco Ladetto, MD, Jeanette K. Doorduijn, MD PhD, Eva Gine, MD, Mats Jerkeman, MD Professor, Ulrich Mey, MD, Michal Szymczyk, MD, Martin Hutchings, MD PhD, Arne Kolstad, MD PhD, Gregor Verhoef, MD PhD, Marek Trneny, MD prof, Maria Gomes da Silva, MD, Christiane Pott, MD PhD, Wolfram Klapper, Michael Unterhalt, PhD, Eva Hoster, PhD

Blood (2019) 134 (Supplement_1): 2816.

https://doi.org/10.1182/blood-2019-127863

Published: 2019

Journal Articles

System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival

Astrid Tschan-Plessl, MD, Eivind Heggernes Ask, Thea Johanne Gjerdingen, Michelle Saetersmoen, Hanna Julie Hoel, Merete Thune Wiiger, Msc, Johanna Olweus, Björn E Wahlin, MD PhD, Amir Horowitz, PhD, Todd A Fehniger, MD PhD, Harald Holte, MD PhD, Arne Kolstad, MD PhD, Karl-Johan Malmberg, MD PhD

Blood (2019) 134 (Supplement_1): 2897.

https://doi.org/10.1182/blood-2019-131359

Published: 2019

Journal Articles

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Blood (2018) 132 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2018-99-110555

Published: 2018

Journal Articles

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Blood (2017) 130 (Supplement 1): 2769.

https://doi.org/10.1182/blood.V130.Suppl_1.2769.2769

Published: 2017

Journal Articles

177 lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Blood (2016) 128 (22): 1780.

https://doi.org/10.1182/blood.V128.22.1780.1780

Published: 2016

Journal Articles

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Arne Kolstad, MD PhD, Lone B Pedersen, Christian Winther Eskelund, Simon Husby, MD, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, MD PhD, Niels S. Andersen, MD PhD, Peter de Nully Brown, MD PhD, Christian H Geisler

Blood (2016) 128 (22): 146.

https://doi.org/10.1182/blood.V128.22.146.146

Published: 2016

Journal Articles

The Health Related Quality of Life Is Maintained Following Treatment of Indolent Non-Hodgkin's Lymphoma Patients with the Novel Effective Antibody Radionuclide Conjugate 177 lu-Satetraxetan-Lilotomab

Arne Kolstad, MD PhD, Matthew Beasley, Michael Bayne, Ingemar Lagerlöf, Noelle O'Rourke, Jostein Dahle, Laurie Baylor Curtis, Åse Østengen, Simon Turner, Roy Hartvig Larsen, Harald Holte

Blood (2016) 128 (22): 5339.

https://doi.org/10.1182/blood.V128.22.5339.5339

Published: 2016

Journal Articles

Identification of Tigit on Intra-Tumor T Cells As a New Target for Immune Checkpoint Blockade in Follicular Lymphoma

Sarah Gothberg, Kanutte Huse, Arne Kolstad, MD PhD, Ole Christian Lingjærde, PhD, Bjørn Østenstad, MD PhD, Erlend Smeland, MD PhD, Ronald Levy, MD, Jonathan Michael Irish, PhD, June Helen Myklebust, PhD

Blood (2016) 128 (22): 917.

https://doi.org/10.1182/blood.V128.22.917.917

Published: 2016

Journal Articles

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Bjørg Bolstad, MSc, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Jostein Dahle, PhD, Nils Bolstad, MD, Roy Hartvig Larsen, PhD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD

Blood (2015) 126 (23): 5118.

https://doi.org/10.1182/blood.V126.23.5118.5118

Published: 2015

Journal Articles

Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials

Simon Husby, MD, Lone Bredo Pedersen, Ulrik Ralfkiær, PhD-student, Christian Garde, Sara Ek, Arne Kolstad, MD PhD, Mats Jerkeman, MD PhD, Anna Laurell, Riikka Räty, Anja Pedersen, Christer Sundström, Marja-Liisa Karjalainen-Lindsberg, Jan Delabie, MD PhD, Erik Clasen-Linde, MD, Christopher Workman, PhD, Christian H Geisler, Kirsten Grønbæk, MD DMSc

Blood (2014) 124 (21): 2994.

https://doi.org/10.1182/blood.V124.21.2994.2994

Published: 2014

Journal Articles

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Jostein Dahle, PhD, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Bjørg Bolstad, MSc, Nils Bolstad, MD, Anne Tierens, MD PhD, Roy Hartvig Larsen, PhD, Jan Alan Alfheim, MSC, MBA, Jan Delabie, MD PhD, Spetalen Signe, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, MD PhD

Blood (2014) 124 (21): 3094.

https://doi.org/10.1182/blood.V124.21.3094.3094

Published: 2014

Journal Articles

Clinical and Immunological Response Following hTERT/Survivin mRNA-Loaded Dendritic Cell Vaccination Combined With Ex-Vivo Expanded T Cell Transfer In Melanoma Patients

Gunnar Kvalheim, MD, PhD, Iris Bigalke, MD, Siri Torhaug, MD, Marianne Lundby, Camilla Mollat, Else-Marit Inderberg Suso, PhD, Arne Kolstad, MD, PhD, Gustav Gaudernack, PhD, Anne-Marie Rasmussen, PhD, Steinar Aamdal, MD, PhD

Blood (2013) 122 (21): 4487.

https://doi.org/10.1182/blood.V122.21.4487.4487

Published: 2013

Journal Articles

Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM

June Helen Myklebust, PhD, Joshua Brody, MD, Ash A. Alizadeh, MD, PhD, Debra K Czerwinski, Arne Kolstad, MD, PhD, Michael R Green, Ph.D., Roch Houot, MD, PhD, Jan Delabie, MD, PhD, Holbrook E Kohrt, MD, PhD, Jonathan M. Irish, PhD, Ronald Levy, MD

Blood (2013) 122 (21): 1768.

https://doi.org/10.1182/blood.V122.21.1768.1768

Published: 2013

Journal Articles

Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy for Patients > 65 Years with Mantle Cell Lymphoma: Results From the Phase I Portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) Trial

Mats Jerkeman, MD PhD, Arne Kolstad, MD, PhD, Anna Laurell, Riikka Räty, Kirsten Grønbæk, MD, DMSc, Lone Bredo Pedersen, Christian H. Geisler, PhD, MD

Blood (2011) 118 (21): 2700.

https://doi.org/10.1182/blood.V118.21.2700.2700

Published: 2011

NARROW

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

177 lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

The Health Related Quality of Life Is Maintained Following Treatment of Indolent Non-Hodgkin's Lymphoma Patients with the Novel Effective Antibody Radionuclide Conjugate 177 lu-Satetraxetan-Lilotomab

Identification of Tigit on Intra-Tumor T Cells As a New Target for Immune Checkpoint Blockade in Follicular Lymphoma

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Clinical and Immunological Response Following hTERT/Survivin mRNA-Loaded Dendritic Cell Vaccination Combined With Ex-Vivo Expanded T Cell Transfer In Melanoma Patients

Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM

Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy for Patients > 65 Years with Mantle Cell Lymphoma: Results From the Phase I Portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only